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Highlights 
 Pseudohypoparathyroidism type Ib (PHP1B) is caused by proximal tubular resistance to parathyroid 
hormone. 
 In few sporPHP1B patients the disease is caused by paternal uniparental isodisomy involving 
chromosome 20q (patUPD20q).  
 We investigated 23 Japanese sporadic PHP1B cases to determine whether patUPD20q can be their cause 
of PHP1B. 
 PatUPD20q was confirmed for two patients. 
 Paternal duplication of the chromosomal region comprising the GNAS locus appears to be a relatively 
common cause of sporPHP1B. 
 
 
ABSTRACT 
Pseudohypoparathyroidism type Ib (PHP1B) is caused by proximal tubular resistance to parathyroid 
hormone that occurs in most cases in the absence of Albright’s Hereditary Osteodystrophy (AHO). Familial 
forms of PHP1B are caused by maternally inherited microdeletions within STX16, the gene encoding syntaxin 
16, or within GNAS, a complex genetic locus on chromosome 20q13.3 encoding Gsα and several splice 
variants thereof. These deletions lead either to a loss-of-methylation affecting GNAS exon A/B alone or to 
epigenetic changes involving multiple differentially methylated regions (DMRs) within GNAS. Broad GNAS 
methylation abnormalities are also observed in most sporadic PHP1B (sporPHP1B) cases. However, with the 
exception of paternal uniparental disomy involving chromosome 20q (patUPD20q), the molecular mechanism 
leading to this disease variant remains unknown. We now investigated 23 Japanese sporPHP1B cases, who 
presented with hypocalcemia, hyperphosphatemia, elevated PTH levels, and occasionally with TSH elevations 
and mild AHO features. Age at diagnosis was 10.6±1.45 years. Calcium, phosphate, and PTH were 6.3±0.23 
mg/dl, 7.7±0.33 mg/dl, and 305±34.5 pg/ml, respectively, i.e. laboratory findings that are indistinguishable 
from those previously observed for Caucasian sporPHP1B cases. All investigated patients showed broad 
GNAS methylation changes. Eleven individuals were homozygous for SNPs within exon NESP and a 
pentanucleotide repeat in exon A/B. Two of these patients furthermore revealed homozygosity for numerous 
microsatellite markers on chromosome 20q raising the possibility of patUPD20q, which was confirmed 
through the analysis of parental DNA. Based on this and our previous reports, paternal duplication of the 
chromosomal region comprising the GNAS locus appears to be a fairly common cause of sporPHP1B that is 
likely to occur with equal frequency in Caucasians and Asians. 
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INTRODUCTION 
Pseudohypoparathyroidism (PHP) is characterized by resistance to parathyroid hormone (PTH) in 
proximal renal tubules that leads to hypocalcemia and hyperphosphatemia (1). Different PHP variants have 
been recognized, which are all associated with loss or severely reduced expression of the alpha-subunit of 
the stimulatory G protein (Gsα) in this portion of the kidney thus causing impaired signal transduction of 
PTH and other hormones via the cAMP/PKA signaling pathway (2, 3). Gsα is encoded by GNAS located on 
the long arm of chromosome 20 (20q13.3), a complex imprinted locus that generates multiple sense and 
antisense transcripts. Through the utilization of alternative first exons and promoters, GNAS furthermore 
gives rise to several additional transcripts. These include the A/B transcript, which may encode an amino-
terminally truncated form of Gsα (4) and non-coding antisense transcripts (AS) (5, 6), as well as transcripts 
encoding the extra-large Gαs variant (XLαs) and a 55-kDa neuroendocrine secretory protein (NESP55). 
Patients affected by PHP type Ia (PHP1A) show resistance to several hormones that mediate their 
actions through G protein-coupled receptors and display various features of Albright's Hereditary 
Osteodystrophy (AHO), including short stature, round face, obesity, brachydactyly, ectopic ossifications, 
and/or various degrees of mental retardation (1). PHP1A is caused by inactivating heterozygous mutations 
involving one of the 13 GNAS exons or introns on the maternal allele. Subjects presenting with certain AHO 
features, but without hormonal resistance, obesity, and mental abnormalities, are classified as 
pseudopseudohypoparathyroidism (PPHP). This disorder is also caused by mutations affecting Gsα, but 
these are located on the paternal GNAS allele, rather than the maternal allele as in PHP1A (7).  
Resistance toward PTH in the proximal renal tubules occurs also in PHP type Ib (PHPIB). These patients 
can furthermore show resistance towards other hormones, particularly towards TSH, and they may present 
with AHO features that can be indistinguishable from those observed in PHP1A (8-11). PHP1B is not 
caused by GNAS mutations involving the region encoding Gsα, but instead by loss-of-methylation (LOM) at 
GNAS exon A/B located within a differentially methylated region (DMR) (7).  LOM can also be observed at 
additional GNAS exons, namely AS and XL, which is usually associated with a gain-of-methylation (GOM) 
at GNAS exon NESP.  
The autosomal dominant (AD) form of PHP1B (AD-PHP1B) can be caused by maternal heterozygous 
deletions in STX16 (3-kb, 4.4-kb, and 24.6-kb deletions), the gene encoding syntaxin-16 located 
approximately 220 kb upstream of GNAS exon A/B (12). These STX16 deletions are associated with LOM 
affecting only GNAS exon A/B (12-14), which leads through unknown mechanisms to a reduction or loss of 
Gsα expression from the maternal allele. Indistinguishable LOM affecting only GNAS exon A/B occurs also 
with a maternal deletion comprising exon NESP and the upstream region (15). 
AD-PHP1B can also be caused by maternally inherited deletions involving NESP and/or AS, which are 
associated with loss of all maternal GNAS methylation imprints (16, 17). Similarly broad methylation 
changes are also observed in most sporadic PHP1B (sporPHP1B) patients, but the molecular mechanism 
underlying these epigenetic changes remains unclear for the majority of these patients. In a few sporPHP1B 
patients the disease is caused by paternal uniparental isodisomy involving chromosome 20q (patUPD20q), 
which includes the GNAS locus (18-22). Such chromosomal rearrangements have not yet been described for 
the Japanese population. We therefore investigated 23 Japanese sporPHP1B patients, all of whom showed 
broad methylation changes involving all four DMRs of the GNAS locus, which led to the identification of 
two patients with patUPD20q. We furthermore mapped the known duplications and assessed the frequency 
of UPD20q based on this and previous reports, which will help guiding the evaluation and genetic 
counseling of sporPHP1B patients. 
 
  
MATERIALS AND METHODS 
Patients and healthy family members 
We investigated 23 Japanese sporPHP1B cases, who had presented with PTH-resistant hypocalcemia and 
hyperphosphatemia, and mild AHO features in some; clinical and laboratory information of most of these 
patients was previously reported (23). None of the available parents, siblings, and children showed 
abnormalities in calcium and phosphate homeostasis. Clinical features, biochemical results, and epigenetic 
findings for each patient are presented in Table 1. 
 
Molecular studies 
The study was approved by the Ethics Committee of Chiba University and the Massachusetts General 
Hospital. Genetic analyses were performed after obtaining informed consent from the patient or parents. 
Genomic DNA was extracted from peripheral blood leukocytes, as described (23). 
 
Methylation analysis 
Southern blot analysis and methylation specific-polymerase chain reaction (MS-PCR) were performed, 
as described (23). Multiplex ligation-dependent probe amplification (MLPA) and methylation specific-
MLPA (MS-MLPA) were performed using the SALSA MLPA kit ME031 GNAS (MRC-Holland, 
Amsterdam, The Netherland) following the manufacturer’s instructions. Analysis of the PCR products was 
performed on an ABI3130 genetic analyzer and using the GeneMapper Software (Applied Biosystems) at 
the DNA Core Facility of the Massachusetts General Hospital. 
 
Analysis of SNPs and microsatellite markers 
The PCR to search for single nucleotide polymorphism was performed with QIAGEN Taq DNA 
polymerase and the other reagents supplied with the same kit following the manufacture’s protocols. PCR 
primers are listed in Supplemental Table 4. The PCR products were purified using ExoSap-IT (Affymetrix) 
and sequenced at the DNA Core Facility of the Massachusetts General Hospital. Analysis of microsatellite 
markers across the entire chromosome 20 was performed by the Center for Human Genetic Research of the 
Massachusetts General Hospital. 
  
RESULTS 
Laboratory and clinical findings in our cohort of sporPHP1B patients 
We investigated a total of 23 Japanese subjects with sporPHP1B; sixteen of these patients were recently 
described (23), while the additional patients had previously not been reported (see Table 1). Parents and 
available siblings of our patients have/had no mineral ion abnormalities. All 23 patients showed, when first 
diagnosed, hypocalcemia and hyperphosphatemia associated with a significant increase in serum PTH 
levels. Seven patients also had elevated TSH levels. Ten patients presented with mild AHO features. Taken 
together, these findings in our cohort of sporPHP1B cases were similar to those observed by us (23,24) 
(Table 2) and others (8,9,11,21). 
 
GNAS methylation status and search for deletions in GNAS and STX16 
MS-MLPA of genomic DNA of all patients revealed broad GNAS methylation changes (see Table 1) that 
are indistinguishable from those previously reported by us (23, 24) and others (8,9,11,21). MLPA provided no 
evidence for an allelic loss within GNAS or STX16; the 3-kb deletion in STX16, which is the most frequent 
cause of AD-PHP1B (24-26), was furthermore excluded in all 23 patients by PCR analysis, as previously 
described (12). The child of patient P24 is reportedly healthy and showed no epigenetic change at the GNAS 
locus. 
 
Analysis of SNPs and microsatellite markers at the GNAS locus 
Paternal uniparental disomy of chromosome 20q (patUPD20q) and the associated methylation changes at 
all four GNAS DMRs had provided a molecular explanation for some of the sporPHP1B patients (18-22). Most 
of these cases had revealed isodisomy rather than heterodisomy, and we therefore first analyzed three frequent 
SNPs (rs1800900, rs1800905, and rs138461295) and the pentanucleotide repeat polymorphism at GNAS exon 
A/B (309F20-GGCGC) (Fig. 1 and Suppl. Table 1) to explore the possibility of patUPD20q in our cohort. 
Eight patients were heterozygous for two or more of these variants, making a duplication of the paternal 
chromosome 20q unlikely. Eleven patients were homozygous for the four SNPs within GNAS and four patients 
were heterozygous for one of these variants. The latter fifteen individuals were therefore analyzed further 
through the analysis of six polymorphic microsatellite markers surrounding the GNAS locus (see Fig. 1 and 
Suppl. Table 2). Two of these individuals revealed homozygosity for all six markers raising the possibility of 
patUPD20q.  
    
Analysis of patients and parents through microsatellite markers across the entire chromosome 20 
We furthermore analyzed numerous polymorphic markers across the entire chromosome 20 for patient 
P44 and both of her parents, as well as for patient P18 and her mother (her father is deceased). The studies 
revealed paternal isodisomy involving the entire long arm of chromosome 20, yet showed bi-parental 
inheritance for the short arm of chromosome 20. Furthermore, MLPA revealed no evidence for an allelic loss 
in the STX16-GNAS region leading us to the conclusion that both sporPHP1B cases are affected by 
patUPD20q (Fig. 2). The non-identical healthy twin brother of P44 showed no evidence for GNAS 
methylation abnormalities, as determined by MS-MLPA. Analysis of microsatellite markers 907-rep2, 
261P9-CA, and D20S171 furthermore excluded patUPD20q; other markers were not informative (data not 
shown). Analysis of these and additional polymorphic markers provided no evidence for patUPD20q for the 
other investigated patients.      
   
DISCUSSION   
Our Japanese sporPHP1B cases affected both sexes equally, and their ages and laboratory abnormalities 
at diagnosis were not significantly different from those previously reported by us (see Table 2) and others 
(8,9,11) for Caucasian sporPHP1B cases. Furthermore, no significant differences in clinical and laboratory 
findings were observed for the two patUPD20q patients presented herein and other previously reported cases 
with duplications involving the long arm of chromosome 20 (see Table 3). Patients with patUPD comprising 
the long arm of chromosome 20, the entire chromosome, and only segments of chromosome 20q showed no 
significant differences with regards to age at disease onset as well as levels of PTH, calcium, and phosphate 
at presentation. This suggests that no another imprinted gene or functionally relevant polymorphisms on 
chromosome 20 contributes to mineral ion homeostasis.  
Dixit et al. had proposed a novel phenotype related to PHP1B due to patUPD20q, namely a relatively high 
birth weight and obesity, which was noticed during infancy and persisted until later in life (22). Moreover, 
macrocephaly and tall stature had been observed as possible additional changes (20). However, at the ages of 
7 and 12 years, respectively, our two patUPD20q patients were only slightly above average in height and 
neither was obese (Fig. 2). Besides GNAS, the long arm of chromosome comprises only one other imprinted 
gene, namely NNAT (20q11.2-q12) encoding neuronatin. Loss of this paternally expressed gene has been 
implicated in obesity (35;38-41), while biparental NNAT expression as in patUPD20q does not seem to be 
associated with changes in weight. However, six of seven previously reported patients with patUPD20q 
comprising the NNAT region were taller than average, while three patients whose UPD regions do not extend 
to this locus were below average for height (see Table 3). This could imply that NNAT contributes to growth. 
UPD is the state in which a chromosomal region or segment is inherited only from a single parent. The 
duplicated region may vary from segmental (interstitial or telomeric) to an entire chromosome. Several 
mechanisms resulting in the formation of UPD have been proposed, including monosomy rescue, trisomy 
rescue, gamate complementation, and post-fertilization errors (27). Clinically relevant consequences resulting 
from UPD include, besides trisomic mosaicism, genomic imprinting disorders and homozygosity for a 
recessive mutation, or a combination of both latter conditions. For example, a homozygous mutation in the 
adenosine deaminase was recently shown to lead to severe combined immunodeficiency because of a paternal 
duplication of the entire chromosome 20, which most likely caused PHP1B besides ADA-SCID (28). 
UPD is a very rare event with an estimated frequency in newborns of 0.029% (29). More frequently, UPD 
is observed as a cause of imprinting disorders. For example, Silver-Russel-Syndrome (SRS) is caused in 5-
10% of the cases by matUPD7 (30, 31), while 3-5% of patients with Angelman syndrome (AS) showed 
patUPD15 (32) and 20% of patients with Prader-Willi syndrome (PWS) revealed matUPD15 (33). 
Furthermore, patUPD6 was detected in 41% of the patients with Transient Neonatal Diabetes Mellitus 
(TNDM) (34) and segmental patUPD11p accounted for 20% of the cases with Beckwith-Wiedemann 
syndrome (BWS) (35). In addition, it appears plausible that matUPD15 causes some forms of central 
precocious puberty since mutations in the imprinted gene MKRN3 were found only in 15 out of 32 
investigated patients (36). 
Since the first description of patUPD20q as a cause of sporPHP1B (18), an additional 10 patients with this 
disorder have been reported (19-22), including those described in this manuscript. Most of these cases (6 out 
11) revealed duplication of only one paternal long arm or the entire chromosome 20 (isodisomy), although the 
boundaries of the duplication were not always conclusively defined (see Fig. 1). The remaining sporPHP1B 
cases had smaller duplications involving chromosome 20q, including a duplication of only 7.6 Mb (20q13.31-
q13.32) (22). Only one previous report had provided evidence for heterodisomy involving the short arm of 
chromosome 20 that was combined with interstitial isodisomy affecting chromosome 20q (20); this very 
infrequent cause of UPD could not be explored in the current study because parental DNA was not available 
for most patients. 
The GNAS methylation changes for our patients with patUPD20q were indistinguishable from those of 
other reported cases with different extents of UPD. This indicates that a maternal segment that is no longer 
present within the duplicated 4.6 Mb region contains regulatory elements that allow establishment or 
maintenance of the normal methylation imprints at GNAS. Because of the telomeric boundaries of the 
duplicated region could not be conclusively defined in four cases, it remains uncertain whether the size of the 
genomic GNAS region that is critical for methylation could be smaller (see Fig.1). 
We had previously reported 22 sporPHP1B patients, one of whom was later shown to have a duplication 
of the entire chromosome 20 (24, 19). Fernandez-Rebollo et al. identified patUPD20q in four out of twenty 
sporPHP1B patients (20), while Jin et al. observed patUPD20 in one out of seven Korean sporPHP1B cases 
(21). We now found two additional patUPD20q cases in our cohort of 23 Japanese sporPHP1B patients, 
suggesting that about 10% of all sporPHP1B cases may be caused by duplication of the paternal long arm of 
chromosome 20, and that all racial backgrounds are equally affected. 
In comparison to the large duplicated regions identified in patUPD20 patients to date, about 20% of all 
patients affected by BWS revealed small duplicated segments in the 11p15.5 region that can be as small as 2.7 
Mb (35, 42). Some of these patUPD11p patients were shown to be mosaic implying that postzygotic 
recombination events had occurred (35, 43, 44), i.e., a mechanism different from that for non-mosaic UPDs 
involving large chromosomal regions. It is conceivable that similarly small paternally duplicated regions 
comprising the GNAS locus can be a cause of some sporPHP1B cases or that mosaicism involving the 
chromosome 20q13 region could explain this disease variant. 
 In conclusion, two patients with patUPD20q were identified among 23 Japanese sporPHP1B cases. When 
combined with data from previous reports, these findings suggest that duplication of the paternal long arm of 
chromosome 20 may be a more frequent cause of sporPHP1B than initially thought and that patUPD20q 
should be considered in all sporPHP1B cases with broad GNAS methylation changes. Establishing patUPD20q 
would provide a molecular definition of their disease thus allowing appropriate genetic counseling. 
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LEGENDS TO FIGURES  
 
Fig. 1: 
Schematic representation of the region on chromosome 20q extending from the GNAS locus to syntaxin 16 
(STX16). Each horizontal thick line shows the extent of paternal uniparental isodisomy for the patients 
described in this report and previously described individuals. The region not conclusively defined as UPD is 
shown by a thin horizontal line. A horizontal broken line shows the position of the paternal heterodisomy of 
chromosome 20p. The two dotted vertical lines delineate the smallest region in which duplication of the 
paternal chromosome 20q may lead to sporadic PHP1B. Exons are indicated by boxes, introns by lines; arrows 
show direction of transcription. P, paternal; M, maternal. Numbers in italic were provided by hg19 (GRCh37) 
assembly. For the patient described in Bastepe et al., 2001, two additional microsatellite markers were 
analyzed (see Supplemental Table 3??  I could not see this table in the Table/Fig file). 
 
 
Fig. 2: 
Microsatellite analysis of pedigrees P44 and P18: Affected individuals are represented by filled symbols; the 
parents are depicted by open symbols (circles=females; squares=male). Results for each microsatellite marker 
are shown below both pedigrees. Bold numbers indicate fully informative markers for the region with paternal 
UPD. Identical alleles have the same gray background colors.  
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Fig. 2 
 
Age (years)
Height (cm)
Weight (kg)
D20S117 180 184 184 178 178 172 182 180 180 151
D20S115 238 238 238 238 238 238 238 238 238 238 20p
D20S186 122 138 138 128 128 126 126 132 132 124
D20S112 224 226 226 220 220 222 220 224 224 222
D20S195 146 146 142 142 142 146 140 146 142 142
D20S107 212 214 210 210 210 216 216 216 208 208 20q
D20S119 117 117 113 113 113 113 109 111 109 109
D20S178 183 189 185 185 185 189 183 187 183 183
D20S196 284 286 263 263 263 263 284 286 286 286
D20S86 315 327 315 315 315 315 327 327
907-rep2 206 210 210 210 210 194 194 218 214 214
261P9-CA 210 216 212 212 212 216 216 216 210 210
806M20-CA 196 196 196 196 196 196 198 198 198 198
543J19-TTA 149 156 149 149 149 149 149 156 149 149
D20S171 140 144 138 138 138 140 140 146 144 144
(+1.2 SDS) (+0.6 SDS)
125.0
(+1.2 SDS)
27.3
160.7
(+1.5 SDS)
48.0
7 12
P44 P18
  
 
 
 
 
 
 
 
 
Table 1. Laboratory and epigenetic findings for the investigated PHP1B patients
Age at Calcium Phosphate intactPTH ALP 1,25(OH)2D TSH
diagnosis (mg/dL) (mg/dL) (pg/mL) (IU/L) (pg/mL) (μU/mL) AHO features
(years) (8.5-10.2) (2.4-4.3)* (10-65) (115-359) (20-60) (0.5-5)
P3 Male 14 none 7.8 4..8 129 493 N/D 1.5 - + - ± - 23
P7 Male 6 loc,convulsion 4.6 10.3 347 N/D 45.6 5.9 RF + - - - 23
P8 Male 3 convulsion 5.2 6.8 720 681 22 4.8 Ob + - ± - 23
P9 Female 9 loc 6.3 7.0 870** 258 N/D 2.4 Ob + - ± - 23
P13 Female 6 convulsion 6.0 6.6 288 325 24.1 2.8 - + - ± - 23
P18 Male 12 muscle cramp 4.8 9.1 139 479 23.6 1.4 - + - - - 23
P20 Male 11 convulsion 7.8 9.6 137 833 46.1 N/D - + - - - 23
P21 Female 12 convulsion 5.7 9.1 1600** 451 31 2.3 Ob, RF,MR + - - - 23
P23 Female 8 convulsion 6.7 8.2 134 579 41.3 5.9 Ob, RF + - - - 23
P24 Female 35 tetany 5.3 5.2 96 237 24.5 5.6 Ob + - ± - 23
P25 Male 8 convulsion 7.1 8.6 340 784 51.2 10.4 RF + - - - 23
P27 Female 12 convulsion 5.4 9.5 360 711 59.1 N/D RF, SM + - - - 23
P29 Male 15 convulsion 4.8 7.2 190 1084 60.8 2.1 - + - - - 23
P32 Male 9 none 6.7 7.4 360 N/D 49.2 1.6 - + - - - 23
P40 Female 9 headache 8.3 5.9 480 727 47.3 3.5 - + - - - 23
P44 Female 7 convulsion 7.6 9.3 330 779 50.7 5.8 RF + - - -
P46 Male 4 convulsion 7.0 7.5 300 1613 N/D 4.4 - + - - -
P52 Male 6 convulsion 6.4 8.5 349 726 60.5 3.3 - + - ± -
P54 Male 13 convulsion 5.7 9.4 146 926 5.9 N/D - + - - - 23
P55 Male 4 convulsion low high high N/D N/D 7.2*** - + - ± -
P56 Male 10 N/D 5.2 6.3 354 N/D N/D N/D N/D + - - -
P57 Female 5 N/D 7.3 7.6 473 918 44.1 16.5 RF + - - -
P58 Male 25 loc, tetany 7.2 5.2 457 263 13.0 1.5 - + - - -
 ***data at the age of 14 years during treatment with alfacalcidol; MS-MLPA, Methylation-Specific Multiplex Ligation-dependent Probe Amplification;
*adult normal range; **elevated PTH was documented by a mid-PTH assay (normal range: 90-270 pg/mL), if the intact PTH assay was not available;
N/D, not determined; loc, loss of consciousness; RF, round face; Ob, Obesity; MR, mental retardation; SM, short metacarpals
Code References
NESP AS XL A/B
Serum biochemical values at diagnosis MS-MLPA
symptomsSex
Table 2. Age at diagnosis and laboratory findings in our Japanese cohort of sporadic PHP1B patients in comparison to our previously
 reported data for Caucasian patients.
sporPHP1B sporPHP1B sporPHP1B sporPHP1B sporPHP1B sporPHP1B sporPHP1B sporPHP1B
Linglart et al., this report Linglart et al., this report Linglart et al., this report Linglart et al., this report
2007 2007 2007 2007
Median 10.0 9.0 5.7 6.4 8.0 7.6 402 335
Mean 10.0 10.6 6.0 6.3 8.2 7.7 634 305
SD 4.61 6.98 1.17 1.08 1.35 1.56 742.9 154.3
SEM 0.98 1.45 0.25 0.23 0.29 0.33 158.4 34.5
N 22 23 22 22 22 22 22 20
PTH 
(pg/ml)
Age at diagnosis 
(years)
Calcium 
(mg/dl)
Phosphate
 (mg/dl)
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Age at diagnosis, height, and laboratory findings in patients with sporPHP1B due to different forms of patUPD20
Age at Calcium Phosphate intact PTH TSH
diagnosis (mg/dL) (mg/dL) (pg/mL) (μU/mL)
case Type of patUPD20q Sex (years) (8.5-10.2) (2.4-4.3) (10-65) (0.5-5)
Bastepe et al.,2011 entire chromosome Female 3.5 7.2 8.0 3685 N/D
Jin et al., 2011 entire chromosome Male 8 5.6 8.1 677 7.2
Bastepe et al.,2001 entire q arm Male 5 7.2 8.1 113 N/D
Fernandez-Rebollo et al., case 2 entire q arm Male 9 8.8 6.5 940 2.0
this report, P18 entire q arm Male 12 4.8 9.1 139 1.4
this report, P44 entire q arm Female 7 7.6 9.3 330 5.8
segmental 20p heterodisomy + 
20q interstitial isodisomy
Fernandez-Rebollo et al., case 1 Segmental 20q13.13-qter Female 26 5.2 5.9 601 N/D
Fernandez-Rebollo et al., case 4 Segmental 20q13.13-qter Male 46 6.4 4.6 127 1.2
Dixit et al., patient 1 Segmental 20q12-q13.33 Male 13 5.0 9.5 345 N/D
Dixit et al., patient 2 Segmental 20q13.31-q13.32 Male 5.5* 9.0* 6.1* 422* 35.0
Serum biochemical values at diagnosis
Patients without duplication of the region comprising NNAT are listed in italics.
 *treatment with cholecalciferol commenced
Fernandez-Rebollo et al., case 3
Male
5 4.8 7.4 292 2.8
Marker Forward primer (5'→3'） Reverse primer(5'→3') Reference
rs1800900 GGCCAGCTTCTCACCTCATA TCTTAGGCACACACCGAGAA
rs1800905 CCGTCCAGATTCTCCTTGTT AGCTGAGCCTCCTCTCTTCC
rs138461295 GCTGCAAGCCAAAGAAGC AACCCTGGTAGCCCGTAG
rs61749697 TCCCGAGTTATCGCACAAGT GATCGGCTGGTGCTGTCC
309F20-GGCGC GGCCGGTTATAAGCTCTGCT GTGCACTCACACGCAAGG 45
Supplemental Table 1. Primer sequences for SNPs analysis
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Table  2. Analysis of SNPs and microsatellite markers of the investigated PHP1B patients
code D20S86 907-rep2 261P9-CA 806M20-CA rs1800900 rs1800905 rs138461295 rs61749697 309F20 543J19-TTA D20S171
P3 A/G A/G T/T T/T 2/3
P7 319/319 194/210 216/216 196/196 G/G G/G T/T T/T 2/3 149/152 144/146
P8 315/319 194/206 216/218 196/196 G/G G/G T/T T/T 3/3 149/149 140/142
P9 319/323 194/210 208/216 198/198 G/G G/G T/T T/T 3/3 149/149 140/142
P13 323/327 194/210 206/218 196/198 G/G G/G T/T T/T 3/3 149/156 144/146
P18 327/327 214/214 210/210 198/198 G/G G/G T/T T/T 3/3 149/149 144/144
P20 319/327 210/214 212/216 196/198 G/G G/G T/T T/T 3/3 149/152 146/148
P21 A/G A/G C/T T/T 3/3
P23 A/G A/G T/T T/T 2/3
P24 323/323 206/210 214/223 196/198 G/G G/G T/T T/T 2/3 140/144
P25 A/G A/G C/T T/T 3/3
P27 A/G A/G C/T T/T 2/3
P29 311/323 194/214 210/216 196/200 G/G G/G T/T T/T 3/3 149/149 144/144
P32 319/319 206/210 212/214 196/196 G/G G/G T/T T/T 3/3 149/156 142/142
P40 A/G G/G T/T T/T 2/3
P44 315/315 210/210 212/212 196/196 G/G G/G T/T T/T 3/3 149/149 138/138
P46 315/323 194/214 212/214 196/196 G/G G/G T/T T/T 3/3 149/149 144/148
P52 A/G A/G T/T T/T 3/3
P54 315/323 194/214 210/216 196/200 G/G G/G T/T T/T 3/3 149/149 140/152
P55 319/323 194/214 210/212 198/200 G/G G/G T/T T/T 149/149 138/146
P56 A/G A/G T/T T/T 3/3
P57 315/319 194/214 212/214 196/198 G/G A/G T/T T/T 2/2 149/149 140/148
P58 319/323 206/218 212/212 196/198 G/G A/G T/T T/T 2/2 149/149 142/144
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